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Changes in virulence and fitness during an epidemic are common among pathogens. Several studies have shown that HIV fitness increases
within a patient during disease progression, while bottlenecks, such as sexual transmission, immune pressure and drug treatment can reduce
fitness. In this study, we analyzed how these opposing forces have shaped HIV-1 fitness over time. Therefore, we compared the replicative fitness
of HIV-1 isolates from newly infected untreated individuals, diagnosed for HIV-1 infection early in the AIDS epidemic in Amsterdam, the
Netherlands, with more recent isolates. Twenty-five early and late HIV-1 isolates, carefully matched for seroconversion time, were competed head-
to-head in a dual infection/competition assay, employing peripheral blood mononuclear cells. In contrast with previous studies, we observed a
trend of increasing fitness over time in the HIV epidemic of Amsterdam. Apparently, the bottleneck, occurring with each transmission event, does
not completely reset the fitness increase acquired during disease progression.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Replication capacity; Fitness; Evolution; Epidemic; TransmissionIntroduction
Fitness is a parameter describing the replicative capacity of
an organism in a particular environment. In the case of HIV,
fitness is affected by multiple factors, depending on the host
environment (i.e., different target cells, immune responses,
antiretroviral treatment), as well as host and viral genetics (Van
Opijnen and Berkhout, 2005). Initial studies on attenuated HIV-
1 variants with a deletion of the nef gene clearly indicated that
reduced virus replication leads to delayed disease progression
(Kirchhoff et al., 1995; Learmont et al., 1999; Dyer et al., 1999;
Birch et al., 2001). Several studies over the past 5 years have
suggested that the ability of HIV to replicate in vitro in primary
human T cells, i.e., the majority of target cells during chronic
HIV-1 infection, is related to pathogenicity and virulence⁎ Corresponding author. Fax: +32 3 247 63 33.
E-mail address: ygali@itg.be (Y. Gali).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.02.021(Quinones-Mateu et al., 2000; Troyer et al., 2005; Ariën et al.,
2005a, 2005b).
Previous work has shown that, within an infected person,
HIV-1 replicative fitness increases during progression of
disease, suggesting that natural constraints such as the innate
and adaptive human immune system are not restrictive enough
to prevent increases in HIV-1 fitness (Quinones-Mateu et al.,
2000; Troyer et al., 2005). Suboptimal antiretroviral treatment,
giving rise to drug resistance mutations, may also influence
fitness. Most primary drug resistance mutations result in a drop
in replicative fitness that is subsequently compensated by
secondary mutations, with a concomitant rebound in fitness
(Harrigan et al., 1998; Martinez-Picado et al., 1999; Nijhuis et
al., 1999; Weber et al., 2005). These observations indicate that
drug-induced bottlenecks are not restrictive enough to perma-
nently reduce the viral fitness. Recently, in vitro studies have
shown that the replicative fitness of different HIV types and
groups correlates with their prevalence in the human popula-
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al., 2005a, 2005b; Ball et al., 2003). Furthermore, we and others
presented data that suggests that the recombinant virus
CRF02_AG has increased fitness compared with subtypes A
and G which may underlie the increased spread of this
recombinant in West Central Africa (Njai et al., 2006; Konings
et al., 2006).
In a previous study, we have compared the replicative fitness
of primary HIV-1 isolates from the beginning of the epidemic
and more recent viruses from the ITM-clinic in Antwerpen,
Belgium. Direct head-to-head competitions in activated periph-
eral blood T cells pointed to a significantly lower fitness of the
more recent HIV-1 isolates (Ariën et al., 2005b; Quinones-
Mateu, 2005). We suggested that serial genetic bottlenecks,
occurring during transmission, could reduce viral fitness
gradually, in accordance with in vitro observations by Yuste et
al. (Yuste et al., 1999). However, a criticism on this study is that
the viruses were not matched for seroconversion date and thus
were not optimally controlled for duration of infection. There-
fore, in the present study we have focused on the relative ex vivo
fitness of primary HIV-1 isolates from patients within the first
9–18 months after infection and studied the change in HIV
fitness over time. To this end, virus isolates from the beginning
of the AIDS epidemic (1986) in Amsterdam, the Netherlands,Table 1
Virus characteristics
Virus ID Sample date TSSc CD4 Plasm
Early viruses
EARLY-01 09-06-1986 288 1.30 5.54
EARLY-02 05-09-1986 322 0.55 4.93
EARLY-03 18-04-1986 336 0.75 4.04
EARLY-04 09-10-1986 317 0.99 4.76
EARLY-05 08-07-1986 397 0.27 4.43
EARLY-06 15-04-1986 306 0.98 4.73
EARLY-07 21-04-1986 399 0.34 4.74
EARLY-08 22-09-1986 350 0.41 4.89
EARLY-09 24-07-1986 300 0.80 4.72
EARLY-10 29-05-1986 364 0.94 4.34
EARLY-11 06-06-1986 410 0.87 4.97
EARLY-12 19-06-1986 313 0.74 3.40
EARLY-13 01-09-1986 359 0.96 4.36
EARLY-14 09-09-1986 396 0.25 4.91
Average 347 0.73 4.63
Late viruses
LATE-01 13-05-1996 426 0.59 3.00
LATE-02 04-09-1996 265 0.30 4.48
LATE-03 31-10-1995 335 0.55 4.93
LATE-04 07-02-1995 399 0.36 4.95
LATE-05 07-10-1998 289 0.45 4.08
LATE-06 23-11-1998 533 1.13 3.40
LATE-07 25-05-2004 302 0.71 4.13
LATE-08 09-06-1998 338 0.52 4.40
LATE-09 10-12-1998 337 1.13 3.88
LATE-10 22-10-2003 310 0.40 3.66
LATE-11 01-07-1997 357 0.35 4.08
Average 354 0.59 4.09
“Early” viruses were isolated in 1986; “late” viruses originate from the period betwee
(in ×109 cells per litre blood); viral load (in Log10 plasma RNA copies/ml); NL: T
France; UK: United Kingdom.were compared with more recent viruses (1996–2004) isolated
in the same city. The virus collection of the Amsterdam Cohort
Studies (ACS) of homosexual men is expected to be
homogeneous with regard to subtype (only subtype B) and
route of transmission (men who have sex with men; MSM) and
is therefore very suitable for evolutionary analysis. Remarkably,
and in contrast to the previous data (Yuste et al., 1999; Ariën et
al., 2005b), our results suggest that HIV-1 may have evolved to
become more fit over time in Amsterdam.
Results
Characterization of early and late HIV-1 isolates
“Early” (1986) and “late” (1996–2003) samples were
selected from HIV-1 infected MSM with known seroconversion
date and without antiretroviral treatment (Table 1). Viruses were
propagated from frozen PBMC in short-term coculture with
activated seronegative donor PBMC. PBMC from one donor
were used to propagate all samples while a second PBMC donor
was used to titre the virus stocks and perform dual infections/
competitions. The time since seroconversion of the “early”
(n=14) and “late” (n=11) viruses was similar (347 versus
354 days, respectively; p=0.89, Mann–Whitney test). Patientsa VL Coreceptor Subtype Age Origin
R5 B 35 NL
R5 B 31 NL
R5 B 33 NL
R5 B 38 NL
R5 B 38 NL
R5 B 47 ES/PT
R5 B 38 NL
R5 B 34 NL
R5 B 44 NL
R5 B 26 SG
R5 B 26 VE
R5 B 34 NL
R5 B 35 NL
R5 B 37 NL
35
R5 B 35 NL
R5 B 44 NL
R5 B 56 NL
R5 B 50 FR
R5 B 40 NL
R5 B 34 NL
R5 B 37 NL
R5 B 31 NL
R5 B 31 NL
R5 B 32 NL
R5 B 29 UK
38
n 1995 and 2004; TSSc: time since seroconversion (in days); CD4+ T cell count
he Netherlands; ES: Spain; PT: Portugal; SG: Singapore; VE: Venezuela; FR:
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lower CD4+ T cell count (730 versus 590 per μl for “early” and
“late”, respectively; p=0.34, Mann–Whitney test) and plasma
viral load (4.63 versus 4.09 log copies/ml for “early” and “late”,
respectively; p=0.51, Mann–Whitney test). All HIV isolates
were non-syncytium inducing (NSI)/CCR5 tropic (R5), as
determined on U87.CD4 cells expressing either CXCR4 or
CCR5 (Table 1). To exclude the presence of drug resistance
mutations, we sequenced the complete Pro gene and the first
335 RT nucleotides. None of the known major resistance
mutations were found, with the exception of a T215 mutation in
the RT of one sample (i.e., Late-02). Since patients selected for
this study were not treated with HAART, this mutation likely
represents transmission and subsequent evolution at this RT
position to reach higher fitness (De Ronde et al., 2001). As
expected from previous studies in the Amsterdam Cohort, all
25 viruses could be classified as subtype B based on their Pro-
RT sequence and subsequent phylogenetic analyses. A
Neighbor-Joining (NJ) phylogenetic tree was constructed to
investigate the genetic distances between early and late HIV-1
isolates (Fig. 1). This analysis demonstrates the absence of
particular clusters in the “early” and “late” samples. As
expected, more sequence heterogeneity is apparent for the
“late” samples (Lukashov and Goudsmit, 2002).Fig. 1. Phylogenetic tree, based on Pro-RT nucleotide sequences of all virus
samples, showing the genetic distances between “early” and “late” HIV-1
isolates. Although there is more sequence heterogeneity in the “late” samples,
particular clusters in the “early” or “late” samples are not observed.Comparing the replicative fitness of early and late HIV-1
isolates in PBMC
All 25 HIV-1 isolates were competed (∼300 dual infections
in total) against each other in activated human PBMC from one
donor. We have previously shown that although total virus
production can differ significantly in PBMC of different donors,
the relative production of each virus (i.e., relative fitness) in
dual infections remains similar with different donors (Qui-
nones-Mateu et al., 2000; Marozsan et al., 2005; Troyer et al.,
2005; Ariën et al., 2005a, 2005b, 2006). The initial viral
inoculum (5×10−4 infectious particles per cell) was removed
24 h after infection and de novo virus production was monitored
by HIV-1 capsid (p24) antigen detection in cell culture
supernatant. Upon peak virus production, viral DNA was
extracted and subsequently PCR amplified and submitted to
heteroduplex tracking assays (HTA) to analyze the virus
mixture. Single virus infections were performed to provide
control samples for HTA analysis. Relative fitness was
calculated as described in materials and methods (Quinones-
Mateu et al., 2000).
In a first, more general approach, we analyzed the mean
relative fitness of each virus (from competitions against all other
24 viruses), both “early” and “late”. A higher mean replicative
fitness was observed for the “late” viruses (W1986=0.77 and
W1996–2004=1.33; p=0.04, paired t test). Fig. 2A shows a
ranking of all viruses according to their mean relative fitness.
Closer examination showed that the same trend occurred in
inter-group fitness, i.e., the competitions of each virus from the
“late” group against all the viruses from the “early” group and
vice versa. The “late” HIV-1 isolates out competed the “early”
viruses in 116 out of 144 competitions (80.6%). The mean
relative fitness (W) of all “early” HIV-1 strains was significantly
lower than that of “late” HIV-1 isolates (inter-group
W1986=0.47 and W1996–2004=1.53; p<0.01, paired t test)
(Fig. 2B). Direct competitions between isolates within the
same group (intra-group fitness) showed that individual
differences in fitness exist but that the average fitness in each
group is ∼1, i.e., not different (Fig. 2B). Finally, Spearman rho
test revealed no significant correlations between the relative
fitness and CD4+ T cell count and between the relative fitness
and time since seroconversion.
Discussion
Two evolutionary phenomena (The Red Queen and Mül-
lers Ratchet) determine viral fitness within an infected
individual and in the epidemic. According to the “Red
Queen” hypothesis (Van Valen, 1974; Clarke et al., 1994),
fitness will increase if several distinct viruses (e.g., the
different members of the quasi-species within a patient)
compete with each other in an ever expanding population and
in the absence of any stringent selection pressure. This
appears to be the case in the chronic phase of an untreated
infection with HIV, which is characterized by extensive viral
replication in activated CD4+ T cells in the absence of strong
immune or drug pressure. In accordance with this hypothesis,
Fig. 2. (A) Fitness ranking. Grey bars represent the mean relative fitness of each individual “early” virus in dual competitions against all other 24 viruses. Black bars
represent the mean relative fitness of each “late” virus from competitions against all other viruses. (B) Mean replicative fitness values for inter-group (EARLY vs.
LATE) versus intra-group (LATE vs. LATE and EARLY vs. EARLY) competitions. Grey diamonds represent the “early” viruses while black squares represent the
“late” viruses. The projection on the y-axis represents the mean of relative fitness values of each virus in competition with all other virus of the same group, the
projection on the x-axis is the mean relative fitness of the same virus in competition with all the viruses from the other group.
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strongly correlates with plasma RNA load and with disease
progression in vivo (Quinones-Mateu et al., 2000; Troyer et
al., 2005). Moreover, we also found that intra-patient HIV-1
replicative fitness increases progressively in function of timeafter seroconversion and correlates with increasing HIV-1 env
genetic diversity (Troyer et al., 2005).
On the contrary, serial bottlenecks result in a decrease of
the quasi-species heterogeneity and viral fitness according to
“Müllers Ratchet” principle (Muller, 1964; Chao, 1990). Such
144 Y. Gali et al. / Virology 364 (2007) 140–146bottlenecks may be induced by strong immune and drug
pressure, but they may also occur during inter-person
transmission events. The “transmission bottleneck” is deduced
from the observation that the quasi-species in the newly in-
fected subject is more homogeneous as compared to that in the
source subject, indicating that only a limited number of clones
(or genotypes) are transmitted (Duarte et al., 1992; Escarmis et
al., 1996).
In this context, we previously compared the replicative
fitness of primary HIV-1 isolates from the beginning of the
epidemic and more recent viruses from the ITM-clinic in
Antwerpen, Belgium (Ariën et al., 2005a, 2005b; Quinones-
Mateu, 2005). Competing HIV-1 isolates from the late eighties
and isolates from 2002 to 2003 revealed that the more recent
HIV-1 isolates replicated significantly less efficiently. The
Antwerp population, however, consisted of heterogeneous hosts
(men and women of diverse ethnicities, different routes of
transmission and durations of infection) and viruses (diverse
subtypes, tropism). Moreover, the time since seroconversion
was unknown and patients in all stages of disease were
represented. To overcome the possible impact of heterogeneity,
the samples from both groups were carefully matched for CD4+
T cell count, viral load and viral subtype (Ariën et al., 2005b).
Remarkably, the current data on the Amsterdam Cohort
suggest a trend towards increased replicative fitness over almost
the same period in time in another West-European city.
Although both studies were performed with the same techniques
by the same team in the same laboratory, there are various
differences in patient and viral characteristics, which might
explain the different outcome. In stark contrast to the Antwerp
cohort, the Amsterdam Cohort is much more homogeneous, i.e.,
exclusively subtype B viruses from MSM living in Amsterdam.
Furthermore, the viruses from Amsterdam were isolated early
after infection (typically between 9 and 18 months) and early
and late groups were primarily matched for time since
seroconversion. Given that the “early” and “late” viruses were
isolated at a time point when viral evolution within each patient
was still limited, the observed fitness differences between the
two comparable and homogenous patients groups, “early” and
“late” in the epidemic, are likely to reflect the effect of the
transmission bottleneck over time.
Recently, Muller et al. (2006) found a lack of change in
HIV virulence over time, as assessed by a number of clinical
markers, i.e., the slope of CD4+ T cell count, CD4:CD8 ratio
and viral set point. This lack of long-term evolution of
virulence markers and the presence of patients with either slow
or rapid progression during the observation period suggests
that both highly virulent and attenuated strains had spread in
the population. Obviously, the set-up of the Swiss study differs
fundamentally from the current study. Muller et al. measured
the outcome of the virus–host interaction in clinical terms and
make broad indirect conclusions on evolution of “virulence”.
In the current study, we have focused on the replicative fitness
as an ex vivo parameter that measures an intrinsic viral
characteristic, that is the result of viral-host interactions, and
that may constitute one of the determinants of overall (clinical)
virulence.Because of the conflicting results on the evolution of HIV
fitness presented in the few studies carried out today and the
uncertainty of the actual effect of transmission on viral fitness, it
is advisable to design larger studies using samples from various
epidemiological settings and that are well-controlled for host
and viral factors (such as mode of transmission, viral subtype,
ethnic background of the patients etc.). Preferentially, samples
from seroconverters should be considered for this kind of
evolutionary analysis. Unfortunately, it may be challenging to
perform these kind of studies on larger scale because well-
documented HIV-1 seroconversion samples from the early years
of the epidemic might be difficult to find.
Materials and methods
Cells
Peripheral blood mononuclear cells (PBMC), obtained from
an HIV-seronegative buffy coat by Ficoll-Hypaque density
gradient centrifugation, were stimulated with 2 μg/ml phyto-
hemagglutinin (PHA) for 3 days and further maintained in
RPMI 1640-2 mM L-glutamine medium supplemented with
10% fetal bovine serum (FBS), 10 mM HEPES, 1 ng/ml
interleukin-2 (IL-2), 100 U/ml penicillin and 100 μg/ml
streptomycin, further referred to as complete medium. The
resulting cell population consists of >90% PHA/IL-2 T blasts.
Patients and viruses
Twenty-five HIV-1-positive MSM (men who have sex with
men) participating in the Amsterdam Cohort Studies were
selected based on the availability of stored infected PBMC,
isolated early after seroconversion. Virus was propagated
starting from cells isolated from fourteen subjects that
seroconverted in the mid eighties (early group) and from eleven
in the late nineties (late group), in short-term cocultures with
HIV-seronegative donor PBMC. Plasma viral load of each
patient was determined with the NASBA assay (Organon)
(Table 1). The coreceptor tropism was determined on U87.CD4
cells expressing either CCR5 or CXCR4 (Table 1). Virus titers
were determined in PHA/IL-2 activated T cells from one HIV-
negative donor. Virus stocks were serially diluted in six-fold
replicates and then added to activated T cells to measure
TCID50. Following 10 days of incubation, supernatant was
harvested and virus production was measured using an in-house
p24 antigen capture ELISA. Tissue culture dose for 50%
infectivity (TCID50) was calculated using the Reed and Muench
(1938) method.
Growth competition assays
Dual infections/competitions were performed in duplicate
with twenty-five primary HIV-1 isolates in PHA/IL-2 activated
T cells from one donor (same donor as for TCID50 determina-
tion and same blood draw) as described earlier (Quinones-
Mateu et al., 2000; Marozsan et al., 2005; Troyer et al., 2005;
Ariën et al., 2005a, 2005b, 2006). Activated T cells were
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(0.0005 MOI). Uninfected cultures were used as HIV-negative
controls and monoinfected cell cultures of each virus corre-
spond to positive controls. The estimated frequency of
recombination between HIV-1 isolates in the dual infection
competition assay is 1% of the dual virus production and well
below the limit of HTA detection (Quinones-Mateu et al.,
2000). Virus mixtures were incubated with 2×105 PBMC at
37 °C in 5% CO2 and washed three times with 1× phosphate-
buffered saline (PBS) 24 h post infection and then resuspended
in complete medium (Ariën et al., 2005a, 2005b, 2006; Njai et
al., 2006). Cell-free supernatant was assayed for p24 antigen
detection 7 and 10 days post infection with an in house HIV-1
p24 antigen capture ELISA (Beirnaert et al., 1998). Two
aliquots of supernatant and cells were harvested at day 10 after
infection and stored at −80 °C for subsequent analysis.
Heteroduplex tracking assay (HTA)
Proviral DNA was extracted from lysed PBMC using the
QIAamp DNA Blood kit (Qiagen, GmbH, Belgium). HIV-1
DNAwas PCR amplified using a set of external primers (envB:
5′-AGAAAGAGCAGAAGACAGTGGCAATGA-3′ and
ED14: 5′-TCTTGCCTGGAGCTGT TTGATGCCCCAGAC-
3′), followed by nested amplification (E80: 5′-CCAATTCCCA-
TACATTATTGTG-3′ and E125: 5′-CAATTTCTGGGTCCC-
CTCCTGAGG-3′). The nested PCR reaction was carried out in
a 100-μl reaction mixture under defined cycling conditions
(Quinones-Mateu et al., 2000; Ariën et al., 2005a). Nested PCR
products from env (C2V3) were analyzed by heteroduplex
tracking assays (HTA) to determine the amount of virus
production in the dual infection/competition experiments, as
described previously (Quinones-Mateu et al., 2000; Ariën et al.,
2005a, 2005b, 2006; Njai et al., 2006). Radiolabeled DNA
probes were PCR amplified from regions of env using the same
primer sets described above, and one of the nested primers was
radiolabeled using T4 polynucleotide kinase and 2 μCi of
[γ-32P] ATP (Quinones-Mateu et al., 2000).
Competitions were analyzed with two different probes
derived from primary HIV-1 isolates unrelated to this study (a
subtype A probe: A1 and a subtype E probe: E3). In previous
studies using diverse HIV-1 subtypes, we have shown that
probe binding and specificity does not significantly differ
among HIV-1 M subtypes (Ariën et al., 2005a). Subsequently,
radiolabeled probes were separated on 1% agarose gels and
purified using the QIAquick gel extraction kit (Qiagen, GmbH,
Belgium). HTA reaction mixtures contained DNA annealing
buffer (100 mM NaCl, 10 mM Tris–HCl [pH 7.8], 2 mM
EDTA), 10 μl of amplified DNA from the competition culture
and 0.1 pmol of radioactive probe DNAwere denatured at 95 °C
for 3 min followed by incubation at 37 °C for 5 min and rapid
transfer on wet ice to allow re-annealing. DNA heteroduplexes
were resolved on 5% TBE non-denaturing polyacrylamide gels
(BIORAD, Belgium) for 1 h 15 min at 200 V. Gels were dried
for 45 min at 80 °C, exposed and scanned with a phosphor
imager (Cyclone®, PerkinElmer, Boston, USA) and analyzed
with OptiQuant (PerkinElmer, Boston, USA).Estimation of viral fitness
The final ratio of two viruses produced in a dual infection
was measured by heteroduplex tracking analysis and com-
pared to the production in monoinfections. Production of
individual HIV isolates in a dual infection (fo) was divided
by the initial proportion in the inoculum (io). This parameter
is referred to as relative fitness (W=fo / io) (Quinones-Mateu
et al., 2000).
Sequencing
The complete HIV-1 protease (Pro) gene and the first 335
codons of the reverse transcriptase (RT) gene were sequenced.
The sequences were generated in the AMC diagnostic unit with
the ViroSeq HIV-1 genotyping kit version 2 (Celera Diagnos-
tics, Alameda, CA, USA). Electrophoresis and data collection
were performed on an ABI PRISM 3730 genetic analyser
(Applied Biosystems, Foster City, CA, USA).
NJ (Neighbor-Joining) trees based upon Kimura 2-parameter
distance matrices were constructed using the MEGA software
package (www.megasoftware.net) and 900 bootstrap replicates
were analyzed.
Statistical analyses
Analyses were conducted with Spearman rho, Mann–
Whitney U and Student's t tests (SPSS v. 12.0 for Windows)
(SPSS Inc., Chicago, IL, U.S.) to calculate correlations and
significance levels.
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